Therapeutic thresholds and mechanisms for primary non-response to infliximab in inflammatory bowel disease

References

• Papamichael K, Rivals-Lerebours O, Billiet T, et al. Long-term outcome of patients with ulcerative colitis and primary non-response to infliximab. J Crohns Colitis. 2016;10(9):1015–1023.
   PubMed Web of Science ®Google Scholar
• Papamichael K, Gils A, Rutgeerts P, et al. Role for therapeutic drug monitoring during induction therapy with TNF antagonists in IBD: evolution in the definition and management of primary nonresponse. Inflamm Bowel Dis. 2015;21(1):182–197.
   PubMed Web of Science ®Google Scholar
• Buhl S, Steenholdt C, Rasmussen M, et al. Outcomes after primary infliximab treatment failure in inflammatory bowel disease. Inflamm Bowel Dis. 2017;23(7):1210–1217.
   PubMed Web of Science ®Google Scholar
• Steenholdt C, Bendtzen K, Brynskov J, et al. Optimizing treatment with TNF inhibitors in inflammatory bowel disease by monitoring drug levels and antidrug antibodies. Inflamm Bowel Dis. 2016;22(8):1999–2015.
   PubMed Web of Science ®Google Scholar
• Brandse JF, van den Brink GR, Wildenberg ME, et al. Loss of infliximab into feces is associated with lack of response to therapy in patients with severe ulcerative colitis. Gastroenterology. 2015;149(2):350–355 e2.
   PubMed Web of Science ®Google Scholar
• Yarur AJ, Jain A, Sussman DA, et al. The association of tissue anti-TNF drug levels with serological and endoscopic disease activity in inflammatory bowel disease: the ATLAS study. Gut. 2016;65(2):249–255.
   PubMed Web of Science ®Google Scholar
• Olsen T, Goll R, Cui G, et al. TNF-alpha gene expression in colorectal mucosa as a predictor of remission after induction therapy with infliximab in ulcerative colitis. Cytokine. 2009;46(2):222–227.
   PubMed Web of Science ®Google Scholar
• Martinez-Borra J, Lopez-Larrea C, Gonzalez S, et al. High serum tumor necrosis factor-alpha levels are associated with lack of response to infliximab in fistulizing Crohn's disease. Am J Gastroenterol. 2002;97(9):2350–2356.
   PubMed Web of Science ®Google Scholar
• Adedokun OJ, Sandborn WJ, Feagan BG, et al. Association between serum concentration of infliximab and efficacy in adult patients with ulcerative colitis. Gastroenterology. 2014;147(6):1296–1307.e5.
   PubMed Web of Science ®Google Scholar
• Bar-Yoseph H, Levhar N, Selinger L, et al. Early drug and anti-infliximab antibody levels for prediction of primary nonresponse to infliximab therapy. Aliment Pharmacol Ther. 2018;47(2):212–218.
   PubMed Web of Science ®Google Scholar
• Brandse JF, Mathot RA, van der Kleij D, et al. Pharmacokinetic features and presence of antidrug antibodies associate with response to infliximab induction therapy in patients with moderate to severe ulcerative colitis. Clin Gastroenterol Hepatol. 2016;14(2):251–258.
   PubMed Web of Science ®Google Scholar
• Edlund H, Steenholdt C, Ainsworth MA, et al. Magnitude of increased infliximab clearance imposed by anti-infliximab antibodies in Crohn's disease is determined by their concentration. Aaps J. 2017;19(1):223–233.
   PubMed Web of Science ®Google Scholar
• Steenholdt C, Palarasah Y, Bendtzen K, et al. Pre-existing IgG antibodies cross-reacting with the Fab region of infliximab predict efficacy and safety of infliximab therapy in inflammatory bowel disease. Aliment Pharmacol Ther. 2013;37(12):1172–1183.
   PubMed Web of Science ®Google Scholar
• Steenholdt C, Bendtzen K, Brynskov J, et al. Optimizing treatment with TNF inhibitors in inflammatory bowel disease by monitoring drug levels and antidrug antibodies. Inflamm Bowel Dis. 2016;22(8):1999–2015.
   PubMed Web of Science ®Google Scholar
• Steenholdt C, Coskun M, Buhl S, et al. Circulating cytokines and cytokine receptors in infliximab treatment failure due to TNF-alpha independent Crohn disease. Medicine (Baltimore). 2016;95:e3417.
   PubMed Web of Science ®Google Scholar
• Gaujoux R, Starosvetsky E, Maimon N, et al. Cell-centred meta-analysis reveals baseline predictors of anti-TNF alpha non-response in biopsy and blood of patients with IBD. Gut. 2019;68(4):604–614.
   PubMed Web of Science ®Google Scholar
• Vande Casteele N, Herfarth H, Katz J, et al. American Gastroenterological Association Institute Technical review on the role of therapeutic drug monitoring in the management of inflammatory bowel diseases. Gastroenterology. 2017;153(3):835–857.e6.
   PubMed Web of Science ®Google Scholar
• Steenholdt C, Brynskov J, Thomsen OO, et al. Individualised therapy is more cost-effective than dose intensification in patients with Crohn's disease who lose response to anti-TNF treatment: a randomised, controlled trial. Gut. 2014;63(6):919–927.
   PubMed Web of Science ®Google Scholar
• Jorgensen KK, Olsen IC, Goll GL, NOR-SWITCH study group, et al. Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial. Lancet. 2017;389(10086):2304–2316.
   PubMed Web of Science ®Google Scholar
• Gonczi L, Vegh Z, Golovics PA, et al. Prediction of short- and medium-term efficacy of biosimilar infliximab therapy. Do trough levels and antidrug antibody levels or clinical and biochemical markers play the more important role? J Crohns Colitis. 2017;11:697–705.
   PubMed Web of Science ®Google Scholar
• Kobayashi T, Suzuki Y, Motoya S, et al. First trough level of infliximab at week 2 predicts future outcomes of induction therapy in ulcerative colitis-results from a multicenter prospective randomized controlled trial and its post hoc analysis. J Gastroenterol. 2016;51(3):241–251.
   PubMed Web of Science ®Google Scholar
• Papamichael K, Van Stappen T, Vande Casteele N, et al. Infliximab concentration thresholds during induction therapy are associated with short-term mucosal healing in patients with ulcerative colitis. Clin Gastroenterol Hepatol. 2016;14(4):543–549.
   PubMed Web of Science ®Google Scholar
• Vande Casteele N, Jeyarajah J, Jairath V, et al. Infliximab exposure-response relationship and thresholds associated with endoscopic healing in patients with ulcerative colitis. Clin Gastroenterol Hepatol. 2019;17(9):1814–1821.e1.
   PubMed Web of Science ®Google Scholar
• Dreesen E, Baert F, Laharie D, et al. Monitoring a combination of calprotectin and infliximab identifies patients with mucosal healing of Crohn's disease. Clin Gastroenterol Hepatol. 2020;18(3):637–646.e11.
   PubMed Web of Science ®Google Scholar
• Steenholdt C, Brynskov J, Thomsen OO, et al. Individualized therapy is a long-term cost-effective method compared to dose intensification in Crohn's disease patients failing infliximab. Dig Dis Sci. 2015;60(9):2762–2770.
   PubMed Web of Science ®Google Scholar
• Gibson DJ, Heetun ZS, Redmond CE, et al. An accelerated infliximab induction regimen reduces the need for early colectomy in patients with acute severe ulcerative colitis. Clin Gastroenterol Hepatol. 2015;13(2):330–335.
   PubMed Web of Science ®Google Scholar
• Kevans D, Murthy S, Mould DR, et al. Accelerated clearance of infliximab is associated with treatment failure in patients with corticosteroid-refractory acute ulcerative colitis. J Crohns Colitis. 2018;12(6):662–669.
   PubMed Web of Science ®Google Scholar
• Nalagatla N, Falloon K, Tran G, et al. Effect of accelerated infliximab induction on short- and long-term outcomes of acute severe ulcerative colitis: a retrospective multicenter study and meta-analysis. Clin Gastroenterol Hepatol. 2019;17(3):502–509.e1.
   PubMed Web of Science ®Google Scholar
• Choy MC, Seah D, Faleck DM, et al. Systematic review and meta-analysis: optimal salvage therapy in acute severe ulcerative colitis. Inflamm Bowel Dis. 2019;25(7):1169–1186.
   PubMed Web of Science ®Google Scholar
• Desai D, Faubion WA, Sandborn WJ. Review article: biological activity markers in inflammatory bowel disease. Aliment Pharmacol Ther. 2007;25(3):247–255.
   PubMed Web of Science ®Google Scholar